What is the appropriate management for bronchial asthma?

Management of Bronchial Asthma

All adults and adolescents with asthma should receive inhaled corticosteroid (ICS)-containing medication and should never be treated with short-acting beta-agonist (SABA) alone. 1, 2

Stepwise Treatment Algorithm

Step 1: Intermittent Symptoms

• Preferred: As-needed low-dose ICS-formoterol for patients with occasional symptoms (<2 times/month, no nocturnal symptoms, FEV1 >80% predicted) 3, 2
• This approach significantly reduces moderate-to-severe exacerbations compared with SABA monotherapy 3

Step 2: Mild Persistent Asthma

• Preferred: Low-dose ICS daily 1
• Alternative: As-needed low-dose ICS-formoterol, which reduces exacerbations compared to SABA alone 1, 3
• Other alternatives: Leukotriene receptor antagonists (montelukast once daily or zafirlukast twice daily), cromolyn, nedocromil, or theophylline 1

Step 3: Moderate Persistent Asthma

• Preferred: Low-dose ICS plus long-acting beta-agonist (LABA), OR medium-dose ICS alone 1
• ICS-LABA combinations demonstrate synergistic anti-inflammatory effects equivalent to or better than doubling the ICS dose 3
• Alternative: Low-dose ICS plus leukotriene receptor antagonist, theophylline, or zileuton 1

Step 4: Moderate-Severe Persistent Asthma

• Preferred: Medium-dose ICS-LABA 1
• For patients using budesonide-formoterol, consider maintenance-and-reliever therapy (MART) regimen 4
• Alternative: Medium-dose ICS plus leukotriene receptor antagonist, theophylline, or zileuton 1

Step 5: Severe Persistent Asthma

• Preferred: High-dose ICS-LABA 1
• Add: Omalizumab (anti-IgE) for patients ≥12 years with allergic asthma (sensitivity to dust mite, cockroach, cat, or dog) 1
• Consider triple combination inhalers (ICS-LABA-LAMA) to improve symptoms, lung function, and reduce exacerbations 3

Step 6: Severe Uncontrolled Asthma

• Preferred: High-dose ICS-LABA plus oral corticosteroids 1
• For adults with severe asthma, use low-dose oral corticosteroids (≤7.5 mg/day prednisone equivalent) as last choice 3
• Add: Omalizumab for allergic phenotype 1
• Consider: Biologic therapy for type 2 asthma (anti-IL-5, anti-IL-5Rα, anti-IL-4Rα monoclonal antibodies) 3, 5
• Consider: Low-dose azithromycin (250-500 mg three times weekly for 26-48 weeks) for persistent symptoms despite step 5 treatment 3
• Consider: Bronchial thermoplasty for patients uncontrolled despite optimized treatment when biologics are unavailable or inappropriate 3, 5

Critical Safety Considerations

LABA Safety

• Never use LABAs as monotherapy for long-term asthma control 1
• LABAs must always be combined with ICS 1, 3
• For youths ≥12 years and adults, LABA is the preferred adjunctive therapy to combine with ICS 1

Corticosteroid Monitoring

• Long-term high-dose ICS may cause systemic adverse effects including osteoporosis, hypothalamic-pituitary-adrenal axis suppression, and increased pneumonia risk 3
• Use the lowest ICS dose that provides acceptable symptom control 1

Quick-Relief Medications

• Short-acting beta-agonists (albuterol, levalbuterol, pirbuterol) are the treatment of choice for acute symptom relief 1
• SABA use >2 days/week for symptom relief (excluding exercise-induced bronchospasm prevention) indicates inadequate control and need to step up treatment 1
• Overuse of SABA (>1 canister/month) is a risk factor for asthma-related death 3

Acute Exacerbation Management

Severe Asthma Features (Immediate Treatment Required)

• Respiratory rate >25 breaths/min, heart rate >110 beats/min, PEF <50% predicted 1
• Cannot complete sentences in one breath 1

Life-Threatening Features

• PEF <33% predicted, silent chest, cyanosis, feeble respiratory effort 1
• Bradycardia, hypotension, exhaustion, confusion, or coma 1
• Normal or high PaCO2 (5-6 kPa) in breathless patient, severe hypoxia (PaO2 <8 kPa), or low pH 1

Immediate Management Protocol

1. High-dose inhaled beta-agonists: Nebulized salbutamol 5 mg or terbutaline 10 mg with oxygen, OR 2 puffs via spacer repeated 10-20 times 1
2. High-dose systemic steroids: Prednisolone 30-60 mg OR IV hydrocortisone 200 mg immediately 1
3. If life-threatening: Add nebulized ipratropium 0.5 mg to beta-agonist 1
4. If life-threatening: Give IV aminophylline 250 mg over 20 minutes (avoid if already taking oral theophyllines) 1

Hospital Admission Criteria

• Any life-threatening features present 1
• Features of severe attack persist after initial treatment 1
• PEF 15-30 minutes after nebulization <33% predicted 1
• Lower threshold for afternoon/evening presentations, recent nocturnal symptoms, previous severe attacks, or social concerns 1

Monitoring and Follow-Up

Regular Assessment

• Schedule visits every 2-4 weeks after initial therapy, then every 1-3 months if responding 3
• Measure and record PEF 15-30 minutes after treatment and according to response 1
• Regular training in correct inhaler technique is essential 3

Referral to Specialist

• Patients requiring step 4 treatment with persistent symptoms despite correct technique and adherence 3
• Doubt about diagnosis, possible occupational asthma, or catastrophic sudden severe (brittle) asthma 1
• Continuing symptoms despite high-dose inhaled steroids or consideration for long-term nebulized bronchodilators 1

Adjunctive Therapies

Allergen Immunotherapy

• Subcutaneous immunotherapy may reduce ICS dosage and improve quality of life and lung function in adults 3
• Sublingual immunotherapy for house dust mite-sensitized adolescents/adults with FEV1 >70% predicted may reduce symptoms and ICS dose 3
• Consider for steps 2-4 in patients with allergic asthma 1

Patient Education and Self-Management

• All patients should have a written asthma action plan 1, 2
• Train patients in proper inhaler technique and peak flow meter use 1
• Educate on difference between "relievers" (bronchodilators) and "preventers" (anti-inflammatory treatment) 1
• Patients should recognize worsening signs, especially nocturnal symptoms 1